Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 32Multiple Myeloma 23Leukemia, Myeloid, Acute 23Lymphoma 17Colorectal Neoplasms 16Breast Neoplasms 14Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Triple Negative Breast Neoplasms 10Sarcoma 9Prostatic Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 9Burkitt Lymphoma 9Ovarian Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, T-Cell 7Glioma 7Endometrial Neoplasms 7Neuroblastoma 6Melanoma 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Central Nervous System Neoplasms 5

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Biopsy × 30 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡